2024-10-24 |
[Newsdesk] Equatorial Guinea intensifies its fight against tuberculosis |
Sanjeet Bagcchi |
|
2024-10-24 |
[Clinical Picture] Rare presentation of rapidly progressive tertiary syphilis in AIDS: a case report of syphilitic gumma |
Bin Peng, Qinxiao Li, Songmei Geng |
|
2024-10-24 |
[Newsdesk] Cholera in Sudan amid war and health system collapse |
Alix Boisson-Walsh |
|
2024-10-24 |
[Newsdesk] WHO framework for investigating novel pathogens |
Udani Samarasekera |
|
2024-10-24 |
[Newsdesk] High-Level Meeting on Antimicrobial Resistance 2024 |
Talha Burki |
|
2024-10-24 |
[Newsdesk] Research in brief |
Priya Venkatesan |
|
2024-10-24 |
[Newsdesk] Infectious disease surveillance update |
Cahal McQuillan |
|
2024-10-24 |
[Obituary] Robert Salata |
Sanjeet Bagcchi |
|
2024-10-24 |
[Profile] Nathan Lo—translating infectious disease models into policy |
Tony Kirby |
|
2024-10-24 |
[Newsdesk] 15th Neglected Tropical Disease NGO Network conference |
Timothy Jesudason |
|
2024-10-24 |
[Editorial] The responsibility of publishing early outbreak data |
The Lancet Infectious Diseases |
|
2024-10-24 |
[Comment] Mucosal nirsevimab levels in respiratory syncytial virus breakthrough bronchiolitis |
Sylvie Pillet, Aymeric Cantais, Blandine Noailly, Fabienne Jospin, Franck Zekre, Oulfa Boussetta-Charfi, Sara Chenafi-Adham, Thomas Bourlet, Slim Fourati, Stéphane Paul |
|
2024-10-24 |
[Media Watch] A shared history |
Claire Lenahan |
|
2024-10-24 |
[Media Watch] COVID-19 and sexual health rights in Africa |
Aimee Ramgolam |
|
2024-10-24 |
[Newsdesk] Médecins Sans Frontières ceases activity in Russia |
Ed Holt |
|
2024-10-24 |
[Correspondence] Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination |
Christine Happle, Markus Hoffmann, Amy Kempf, Inga Nehlmeier, Metodi V Stankov, Noemi Calderon Hampel, Torsten Witte, Stefan Pöhlmann, Georg M N Behrens, Alexandra Dopfer-Jablonka |
|
2024-10-24 |
[Media Watch] Globalisation and COVID-19 |
Matilda Lawson |
|
2024-10-24 |
[Corrections] Correction to Lancet Infect Dis 2024; published online Sept 10. https://doi.org/10.1016/S1473-3099(24)00585-1 |
|
|
2024-10-24 |
[Correspondence] Financing infectious disease services in hospitals: a common public good |
Joseph D Tucker |
|
2024-10-24 |
[Media Watch] Vaccine hesitancy in Scandinavia |
Hollie Sherwood-Martin |
|
2024-10-24 |
[Comment] The worsening mpox outbreak in Africa: a call to action |
Krutika Kuppalli, Jake Dunning, Inger Damon, Daniel Mukadi-Bamuleka, Placide Mbala, Dimie Ogoina |
|
2024-10-24 |
[Correspondence] ArboTracker: a multipathogen dashboard and data platform for arbovirus seroprevalence studies |
Mairead G Whelan, Harriet Ware, Himanshu Ranka, Sean Kenny, Sabah Shaikh, Yannik Roell, Shaila Akter, Anabel Selemon, Emilie Toews, May Chu, Niklas Bobrovitz, Rahul K Arora, Thomas Jaenisch |
|
2024-10-24 |
[Correspondence] Mpox outbreak—tecovirimat resistance, management approaches, and challenges in HIV-endemic regions |
Wyvine Ansima Bapolisi, Susanne Krasemann, Misaki Wayengera, Bruce Kirenga, Esto Bahizire, Espoir Bwenge Malembaka, Joseph Nelson Siewe Fodjo, Robert Colebunders, Patrick DMC Katoto |
|
2024-10-24 |
[Correspondence] Potential vertical transmission of Oropouche virus during the current outbreak |
Athina Samara, Conrado Milani Coutinho, Philip Veal, Jane Osborne, Geraldo Duarte, Shamez Ladhani, Asma Khalil |
|
2024-10-24 |
[Correspondence] Limitations of mpox lateral flow tests in assessing orthopoxvirus immunity |
Toby Jones, Scott Jones, Bethany Hicks, Hannah Selman, Cathy Rowe, Ashley D Otter |
|
2024-10-24 |
[Correspondence] Mpox—is there a more dangerous new clade? |
Christian Hoffmann |
|
2024-10-24 |
[Correspondence] Oropouche virus genomic surveillance in Brazil |
Filipe Romero Rebello Moreira, João Victor Rodrigues Dutra, André Henrique Barbosa de Carvalho, Clarisse Rezende Reis, Jéssica Silqueira Hickson Rios, Marisa de Oliveira Ribeiro, Monica Barcellos Arruda, Patricia Alvarez, Renan Pedra Souza, Carolina Voloc |
|
2024-10-24 |
[Correspondence] Oropouche fever: reports of vertical transmission and deaths in Brazil |
Paulo Ricardo Martins-Filho, Thialla Andrade Carvalho, Cliomar Alves dos Santos |
|
2024-10-24 |
[Articles] Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance |
Deus S Ishengoma, Celine I Mandara, Catherine Bakari, Abebe A Fola, Rashid A Madebe, Misago D Seth, Filbert Francis, Creyton C Buguzi, Ramadhan Moshi, Issa Garimo, Samwel Lazaro, Abdallah Lusasi, Sijenunu Aaron, Frank Chacky, Ally Mohamed, Ritha J A Njau, |
|
2024-10-24 |
[Comment] Resistant malaria parasites gaining momentum in Africa |
Eulambius M Mlugu, Arjen M Dondorp, Karen I Barnes |
|
2024-10-24 |
[Articles] Effect of indoor residual spraying on sandfly abundance and incidence of visceral leishmaniasis in India, 2016–22: an interrupted time-series analysis and modelling study |
Luc E Coffeng, Sake J de Vlas, Rudra Pratap Singh, Ananthu James, Joy Bindroo, Niteen K Sharma, Asgar Ali, Chandramani Singh, Sadhana Sharma, Michael Coleman |
|
2024-10-24 |
[Comment] A model of vector-targeted interventions for visceral leishmaniasis |
Christine Petersen |
|
2024-10-24 |
[Comment] Edging towards a third dengue vaccine |
Annika B Wilder-Smith, David O Freedman, Annelies Wilder-Smith |
|
2024-10-24 |
[Articles] Efficacy and safety of Butantan-DV in participants aged 2–59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil |
Mauricio L Nogueira, Monica A T Cintra, José A Moreira, Elizabeth G Patiño, Patricia Emilia Braga, Juliana C V Tenório, Lucas Bassolli de Oliveira Alves, Vanessa Infante, Daniela Haydee Ramos Silveira, Marcus Vínicius Guimarães de Lacerda, Dhelio Batista |
|
2024-10-24 |
[Articles] Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial |
Ahmed H Fahal, Eiman Siddig Ahmed, Sahar Mubarak Bakhiet, Osama Elhadi Bakhiet, Lamis Ahmed Fahal, Abubakar Ahmed Mohamed, El Semani Widaa Mohamedelamin, Mustafa El Nour Bahar, Hadil Yassir Attalla, Emmanuel Edwar Siddig, Najwa A Mhmoud, Ahmed Mudawi Musa |
|
2024-10-24 |
[Comment] Lessons learnt from conducting a randomised clinical trial in eumycetoma |
Rosanne Sprute, Oliver A Cornely |
|
2024-10-24 |
[Articles] Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial |
Isabel Leroux-Roels, Chittappen Kandiyil Prajeeth, Amare Aregay, Niranjana Nair, Guus F Rimmelzwaan, Albert D M E Osterhaus, Simone Kardinahl, Sabrina Pelz, Stephan Bauer, Valentino D'Onofrio, Azhar Alhatemi, Bart Jacobs, Fien De Boever, Sharon Porrez, Gw |
|
2024-10-24 |
[Comment] A promising boost for the Rift Valley fever vaccine pipeline |
Saskia Bronder, Martina Sester |
|
2024-10-24 |
[Articles] Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial |
Glenda E Gray, Kathryn Mngadi, Ludo Lavreys, Steven Nijs, Peter B Gilbert, John Hural, Ollivier Hyrien, Michal Juraska, Alex Luedtke, Philipp Mann, M Juliana McElrath, Jackline A Odhiambo, Daniel J Stieh, Janine van Duijn, Azwidihwi N Takalani, Wouter Wil |
|
2024-10-24 |
[Comment] The need for novel approaches to HIV-1 vaccine development |
Clara Lehmann, Philipp Schommers |
|
2024-10-24 |
[Articles] Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial |
Santhosh Kumar Ghadge, Martina Schneider, Katrin Dubischar, Laura Wagner, Vera Kadlecek, Michaela Obersriebnig, Romana Hochreiter, Anton Klingler, Julian Larcher-Senn, Ulla Derhaschnig, Wolfgang Bender, Susanne Eder-Lingelbach, Nicole Bézay |
|
2024-10-24 |
[Comment] Boosting immunity to protect from tickborne Lyme disease |
Nicole Baumgarth |
|
2024-10-24 |
[Articles] Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study |
Ming Hong Choi, Eric Yuk Fai Wan, Ian Chi Kei Wong, Esther Wai Yin Chan, Wing Ming Chu, Anthony Raymond Tam, Kwok Yung Yuen, Ivan Fan Ngai Hung |
|
2024-10-24 |
[Comment] Antiviral therapy for patients with COVID-19: mix and match |
Karolina Akinosoglou, Charalambos Gogos |
|
2024-10-24 |
[Grand Round] Renal transplantation using kidneys from a donor with high grade cytomegalovirus viraemia: case report and literature review |
Kasra Shirini, Shani Kamberi, Cynthia Drachenberg, Abdolreza Haririan, Kapil Saharia, Raphael P H Meier |
|
2024-10-24 |
[Review] The inclusion of children and adolescents in tuberculosis diagnostic development and evaluation–a consensus statement |
Else M Bijker, Lyn Horn, Sylvia LaCourse, Emily L MacLean, Ben J Marais, Mark P Nicol, Laura Olbrich, James A Seddon, Jayne S Sutherland, Rinn Song, Heather J Zar, Devan Jaganath, Child TB Diagnostics Consensus Group |
|
2024-10-24 |
[Personal View] Lassa fever research priorities: towards effective medical countermeasures by the end of the decade |
Kristine A Moore, Julia T Ostrowsky, Angela J Mehr, Rebecca A Johnson, Angela K Ulrich, Nicolina M Moua, Petra C Fay, Peter J Hart, Josephine P Golding, Virginia Benassi, Marie-Pierre Preziosi, Ifedayo M Adetifa, George O Akpede, William K Ampofo, Danny A |
|
2024-10-24 |
[Personal View] Measures to prevent and treat Nipah virus disease: research priorities for 2024–29 |
Kristine A Moore, Angela J Mehr, Julia T Ostrowsky, Angela K Ulrich, Nicolina M Moua, Petra C Fay, Peter J Hart, Josephine P Golding, Virginia Benassi, Marie-Pierre Preziosi, Christopher C Broder, Emmie de Wit, Pierre B H Formenty, Alexander N Freiberg, E |
|
2024-09-26 |
[Clinical Picture] First report of deep cutaneous fungal infection caused by Nigrograna hydei |
Shu-Fen Wang, Jia-Yi Liu, Fang-Fang Bao, Yong-Xia Liu, Chang-Ping Yu, Mei Wu, Fu-Ren Zhang |
|
2024-09-26 |
[Editorial] doxyPEP: a controversial new tool against STIs |
The Lancet Infectious Diseases |
|
2024-09-26 |
[Newsdesk] HIV stigma in health-care settings in Europe and central Asia |
Sanjeet Bagcchi |
|
2024-09-26 |
[Newsdesk] Global update on hypervirulent Klebsiella pneumoniae |
Manjulika Das |
|
2024-09-26 |
[Newsdesk] Research in brief |
Priya Venkatesan |
|
2024-09-26 |
[Obituary] Tengiz Tsertsvadze |
Sanjeet Bagcchi |
|
2024-09-26 |
[Profile] Farah Qamar—tackling paediatric infectious diseases |
Tony Kirby |
|
2024-09-26 |
[Newsdesk] Global upsurge in dengue in 2024 |
Priya Venkatesan |
|
2024-09-26 |
[Newsdesk] Infectious diseases surveillance update |
Tanzina Islam |
|
2024-09-26 |
[Newsdesk] Polio vaccination campaign in Gaza |
Talha Burki |
|
2024-09-26 |
[Newsdesk] Mpox emergency in Africa |
Esther Nakkazi |
|
2024-09-26 |
[Media Watch] Facing COVID-19 in South Africa |
Jonathan Blott |
|
2024-09-26 |
[Media Watch] Biopolitical precarity for women with HIV in South Africa |
Emma Starbuck |
|
2024-09-26 |
[Media Watch] Antiblackness in the Ebola response in Sierra Leone |
Elizabeth Haslam |
|
2024-09-26 |
[Corrections] Correction to Lancet Infect Dis 2024; published online Aug 12. https://doi.org/10.1016/S1473-3099(24)00357-8 |
|
|
2024-09-26 |
[Correspondence] Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south |
Dhammika Leshan Wannigama, Mohan Amarasiri, Phatthranit Phattharapornjaroen, Cameron Hurst, Charin Modchang, John Jefferson V Besa, Kazuhiko Miyanaga, Longzhu Cui, Stefan Fernandez, Angkana T Huang, Puey Ounjai, Pathogen Hunters Research Team, Andrew C Si |
|
2024-09-26 |
[Correspondence] Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance |
Thibaut Vanbaelen, Sheeba Santhini Manoharan-Basil, Chris Kenyon |
|
2024-09-26 |
[Comment] Re-evaluating polio vaccination strategies in Nepal: transitioning from OPV to fIPV for sustained immunity |
Bhuvan Saud, Saroj Adhikari |
|
2024-09-26 |
[Correspondence] The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus |
Min Du, Min Liu, Ben Niu, Jue Liu |
|
2024-09-26 |
[Correspondence] Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant |
Yu Kaku, Keiya Uriu, Kaho Okumura, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Jumpei Ito, Kei Sato |
|
2024-09-26 |
[Media Watch] Tuberculosis in the USA in 1935 |
Sanjeet Bagcchi |
|
2024-09-26 |
[Media Watch] Understanding outbreak preparedness |
Manjulika Das |
|
2024-09-26 |
[Correspondence] Enhancing wastewater testing for H5N1 surveillance |
Ranu S Dhillon, Abraar Karan, Devabhaktuni Srikrishna |
|
2024-09-26 |
[Correspondence] Gonorrhoea and chlamydia screening for asymptomatic people with HIV and HIV PrEP users: open issues |
Angelo Roberto Raccagni, Antonella Castagna, Silvia Nozza |
|
2024-09-26 |
[Correspondence] First diagnoses of Oropouche virus in Europe: how can we strengthen communication and preparedness globally? |
Concetta Castilletti, Antonio Mori, Elena Pomari, Andrea Matucci, Giulia Martelli, Salvatore Curiale, Andrea Angheben, Federico Giovanni Gobbi |
|
2024-09-26 |
[Correspondence] Tracking the spread of avian influenza A(H5N1) with alternative surveillance methods: the example of wastewater data |
Francesco Branda, Massimo Ciccozzi, Fabio Scarpa |
|
2024-09-26 |
[Corrections] Correction to Lancet Infect Dis 2024; 24: e484 |
|
|
2024-09-26 |
[Media Watch] Living with our distant relatives |
Claire Lenahan |
|
2024-09-26 |
[Articles] Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65–85 years in the USA: a multicent |
Joseph Eiden, Carlos Fierro, Alexander White, Matthew Davis, Margaret Rhee, Mark Turner, Bryan Murray, Renee Herber, Roger Aitchison, David Marshall, Michael J Moser, Robert Belshe, Harry Greenberg, Kathleen Coelingh, Yoshihiro Kawaoka, Gabriele Neumann, |
|
2024-09-26 |
[Comment] Bolstering influenza protection for older adults |
Suryaprakash Sambhara, Paul R Knight |
|
2024-09-26 |
[Articles] Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial |
Heather L Platt, Christopher Bruno, Erik Buntinx, Enrique Pelayo, Diego Garcia-Huidobro, Elizabeth A Barranco-Santana, Folke Sjoberg, Joon Young Song, Carlos G Grijalva, Walter A Orenstein, Leslie Morgan, Doreen Fernsler, Weifeng Xu, Muhammad Waleed, Jian |
|
2024-09-26 |
[Comment] Adult pneumococcal vaccination: what are the gaps? |
Claire von Mollendorf, Paul V Licciardi |
|
2024-09-26 |
[Articles] Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial |
Sarah E Silk, Wilmina F Kalinga, Jo Salkeld, Ivanny M Mtaka, Saumu Ahmed, Florence Milando, Ababacar Diouf, Caroline K Bundi, Neema Balige, Omar Hassan, Catherine G Mkindi, Stella Rwezaula, Thabit Athumani, Sarah Mswata, Nasoro S Lilolime, Beatus Simon, H |
|
2024-09-26 |
[Articles] Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study |
Oleksandr Korotych, Jay Achar, Elmira Gurbanova, Arax Hovhannesyan, Nino Lomtadze, Ana Ciobanu, Alena Skrahina, Gunta Dravniece, Liga Kuksa, Michael Rich, Naira Khachatryan, Myroslava Germanovych, Abdullat Kadyrov, Iana Terleieva, Irada Akhundova, Malik A |
|
2024-09-26 |
[Comment] Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosis |
Tom Decroo, Anita Mesic, Ine Decuyper |
|
2024-09-26 |
[Comment] Getting closer to an effective multi-stage malaria vaccine |
Carlota Dobaño, Gemma Moncunill, Quique Bassat |
|
2024-09-26 |
[Articles] Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial |
Cissy Kityo, Ivan K Mambule, Joseph Musaazi, Simiso Sokhela, Henry Mugerwa, Gilbert Ategeka, Fiona Cresswell, Abraham Siika, Josphat Kosgei, Reena Shah, Logashvari Naidoo, Kimton Opiyo, Caroline Otike, Karlien Möller, Arvind Kaimal, Charity Wambui, Veerle |
|
2024-09-26 |
[Comment] Implementing long-acting injectable cabotegravir and rilpivirine in Africa |
Chloe Orkin, Kyle Ring |
|
2024-09-26 |
[Articles] Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design |
Jean-Michel Molina, Beatrice Bercot, Lambert Assoumou, Emma Rubenstein, Michele Algarte-Genin, Gilles Pialoux, Christine Katlama, Laure Surgers, Cécile Bébéar, Nicolas Dupin, Moussa Ouattara, Laurence Slama, Juliette Pavie, Claudine Duvivier, Benedicte Lo |
|
2024-09-26 |
[Comment] Doxycycline for STIs in men who have sex with men: the next steps |
Troy Grennan, Ann N Burchell |
|
2024-09-26 |
[Articles] Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis |
Tiana Carina Schwab, Lisa Perrig, Pauline Carlotta Göller, Freddy Fernando Guebely De la Hoz, Adrien Philippe Lahousse, Beatrice Minder, Gunar Günther, Orestis Efthimiou, Shaheed Vally Omar, Matthias Egger, Lukas Fenner |
|
2024-09-26 |
[Comment] Time to change to next-generation sequencing for management of drug-resistant tuberculosis? |
Annelies Van Rie, Rob Warren |
|
2024-09-26 |
[Personal View] Urgent considerations for booster vaccination strategies against Ebola virus disease |
Wim Adriaensen, Selien Oostvogels, Yves Levy, Bailah Leigh, Hugo Kavunga-Membo, Deborah Watson-Jones |
|
2024-09-26 |
[Personal View] Evaluation of a single-dose HPV vaccine strategy for promoting vaccine, health, and gender equity |
Mathew Mercuri, Kristy Hackett, Ruanne V Barnabas, Claudia I Emerson |
|
2024-09-26 |
[Articles] Association of nirmatrelvir–ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study |
Huwen Wang, Yuchen Wei, Chi Tim Hung, Guozhang Lin, Xiaoting Jiang, Conglu Li, Katherine Min Jia, Carrie Ho Kwan Yam, Tsz Yu Chow, Janice Ying-en Ho, Yawen Wang, Shi Zhao, Zihao Guo, Kehang Li, Aimin Yang, Chris Ka Pun Mok, David S C Hui, Eng Kiong Yeoh, |
|
2024-09-26 |
[Comment] Oral antivirals for acute symptoms and post-acute sequelae in SARS-CoV-2 infection |
Vicente Soriano, Víctor Moreno-Torres |
|
2024-09-26 |
[Historical Review] Social histories of public health misinformation and infodemics: case studies of four pandemics |
Sabrina L Jin, Jessica Kolis, Jessica Parker, Dylan A Proctor, Dimitri Prybylski, Claire Wardle, Neetu Abad, Kathryn A Brookmeyer, Christopher Voegeli, Howard Chiou |
|
2024-09-26 |
[Review] Consensus definitions in imported human schistosomiasis: a GeoSentinel and TropNet Delphi study |
Francesca Tamarozzi, Cristina Mazzi, Spinello Antinori, Marta Arsuaga, Sören L Becker, Emmanuel Bottieau, Daniel Camprubi-Ferrer, Eric Caumes, Alexandre Duvignaud, Martin P Grobusch, Stephane Jaureguiberry, Sabine Jordan, Andreas Mueller, Andreas Neumayr, |
|
2024-08-22 |
[Newsdesk] Global Sanitation Summit 2024 |
Manjulika Das |
|
2024-08-22 |
[Clinical Picture] Strongyloides stercoralis hyperinfection syndrome |
Lemna Jacob, Ayan Basu, Dipankar Paul, Yogiraj Ray, Nazneen Nahar Begam, Christy Varghese John |
|
2024-08-22 |
[Newsdesk] Chad eliminates gambiense sleeping sickness |
Alix Boisson-Walsh |
|
2024-08-22 |
[Comment] Waiting is no longer an option for household contacts of people with drug-resistant tuberculosis |
Jean Pannikottu, Anja Reuter, Elize Pietersen, Goodman Makhanda, Johnny Daniels, Busisiwe Beko, Ivy Apolisi, Jennifer Furin |
|